# Controlled Level EVERolimus in Acute Coronary Syndromes

Study · id `cardio:ct-nct01529554` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01529554](<https://clinicaltrials.gov/study/NCT01529554>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01529554

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT01529554. Randomized; quadruple masking; primary purpose treatment. Start 2015-01-08 (actual); primary completion 2021-11-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 1/2
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT01529554, source copy `cardio:ctgov-nct01529554-2021-12-03`, retrieved 2026-10-26)
- Started: 2015-01-08 (actual) (ClinicalTrials.gov record NCT01529554, source copy `cardio:ctgov-nct01529554-2021-12-03`, retrieved 2026-10-26)
- Primary completion: 2021-11-29 (actual) (ClinicalTrials.gov record NCT01529554, source copy `cardio:ctgov-nct01529554-2021-12-03`, retrieved 2026-10-26)
- Completion: 2021-11-29 (actual) (ClinicalTrials.gov record NCT01529554, source copy `cardio:ctgov-nct01529554-2021-12-03`, retrieved 2026-10-26)
- Countries: Germany; Switzerland (ClinicalTrials.gov record NCT01529554, source copy `cardio:ctgov-nct01529554-2021-12-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01529554-2021-12-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Controlled Level EVERolimus in Acute Coronary Syndromes
- Acronym: CLEVER-ACS
- Condition: Acute Coronary Syndromes
- Intervention (Drug): Everolimus
- Intervention (Drug): Placebo
- Lead sponsor: University of Zurich
- Lead sponsor class: OTHER
- Collaborator: Swiss National Science Foundation
- Collaborator class: OTHER
- Collaborator: Novartis
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: University of Zurich (`cardio:org-university-of-zurich`)
- Registry lists this organization as a collaborator: Swiss National Science Foundation (`cardio:org-swiss-national-science-foundation`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial (`cardio:pubmed-35092722`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Mammalian Target of Rapamycin Inhibition in Patients With ST-Segment Elevation Myocardial Infarction (`cardio:pubmed-36049557`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Microcirculatory Resistance After Primary Percutaneous Coronary Intervention Predicts Residual Myocardial Damage and Scar Formation (`cardio:pubmed-39921502`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2cbb5ed1f978cb8d809a53ffd5545ef8ec8212ff8afdcdfc29c4e10f53dd66fe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
